Bristol-Myers Decries Blue Cross Unit's Last-Minute Dropout
Celgene and parent Bristol-Myers Squibb expressed frustration Tuesday about the timing of a Blue Cross unit's decision to bow out as a plaintiff in New Jersey federal court antitrust litigation accusing...To view the full article, register now.
Already a subscriber? Click here to view full article